07 Jan HIV Drug Resistance in South Africa: Capacitating Local Public Health Managers to Identify Early Warning Signs
JPS Africa is collaborating and supporting the World Health Organization (WHO) and the National Department of Health and in undertaking HIV Drug Resistance (HIVDR) surveillance across provinces in South Africa. In recent years, the rapid scale up of ART for HIV infection in resource-limited countries has been identified as an international healthcare priority. Sub-Saharan Africa remains the most affected region with a total of 24.7 million which is 73% of the total number of people estimated to be living with HIV around the globe. At the end of 2015, SANAC estimated that 6.4 million South Africans are living with HIV with approximately 2.8 million on anti-retroviral therapy. Scaling-up ART in SA comprises the use of standardized and simplified treatment regimens that are consistent with international guidelines. The emergence and transmission of HIV drug resistance (HIVDR) is an unavoidable consequence of ART, even when appropriate drugs are prescribed and adherence is maximally...